Division Head and Women's Auxiliary Millennium Chair in Haematology/Oncology, The Hospital for Sick Children, Senior Associate Scientist in the Child Health Evaluative Sciences Program, SickKids Research Institute
President and CEO, Azimuth Health Group
Dr. Jennifer Zelmer is President of Azimuth Health Group. In this capacity, she provides a range of advisory services to local, national, and international clients who seek to advance health and health care. In addition, she is the Editor-in-Chief of Healthcare Policy, an Adjunct Faculty Member at the University of Victoria, Faculty/Advisor to the Canadian Foundation for Healthcare Improvement, and serves on a range of health-related advisory committees and boards.
Prior to founding Azimuth Health Group, Jennifer held a series of progressively responsible leadership positions in Canada and abroad, mostly recently as Executive Vice President at Canada Health Infoway, where she was executive lead for the organization’s national clinical adoption, innovation, consumer health, and communications programs, as well its Ontario investment portfolio. Before joining Infoway, Jennifer served as Chief Executive Officer of the International Health Terminology Standards Development Organization and as Vice President at the Canadian Institute for Health Information.
Jennifer received her PhD and MA in economics from McMaster University and her B.Sc. in health information science from the University of Victoria.
President & CEO, Colorectal Cancer Association of Canada
Barry D. Stein, B. Com., B.C.L., LL.B., graduated from McGill University. He has been a member of the Bar of Quebec since 1981. Barry has established a prominent position in the fields of commercial and corporate law with the law firm of GWBR LLP.
His numerous business contacts have also enabled many of his clients to share in successful joint ventures and he has actively participated in the reorganization of management and in the restructuring of many corporations. He regularly represents his clients both nationally and internationally in mergers and acquisitions and he has significantly enhanced their position as a result of same.
A significant portion of his practice is also devoted to labour law as well as litigation. An accomplished negotiator and mediator, he has negotiated many collective agreements in Quebec and appears before administrative tribunals on a regular basis.
With an impressive knowledge in health systems across the country and access to treatment issues, Barry has been involved in leading cases for reimbursement of out of country in health care costs. He also represents the interests of patients be government health agencies and ministries both on a Federal and Provincial level.
Barry sits on the Board of Directors of several corporations including several not for profit organizations and foundations such as The Donald Berman Foundation and Tikva Children’s Foundation.
Barry was a founder and vice president of Gilda’s Club, a cancer wellness center formerly in Montreal. He is a member of the Coalition Priorité Cancer au Québec and actively participates on the patient’s advisory committee. He is also member of the Canadian Partnership Against Cancer National Colorectal Cancer Screening Network.
As the president of the Colorectal Cancer Canada (“CCC”) he actively represents the interests of cancer patients and speaks regularly to medical professionals, industry, government, and patient groups across Canada and Internationally about colorectal cancer, Patient Values and Preferences, Clinical Trials, Informed Consent, Young Adults with Cancer, Personalized Medicine and Companion Diagnostics, Biosimilars, Colorectal Cancer Screening, Foods that Fight Cancer and other CCC programs and research projects.
Under Barry’s stewardship, Colorectal Cancer Canada has developed national awareness and educational programs and support for patients and their families. Barry has been a key advocate for colorectal cancer screening initiatives, patient and physician education and multidisciplinary health professional consensus statements and guidelines as well as for primary prevention and equal and timely access to effective treatment to improve patient outcomes across Canada particularly in light of the development of precision medicine.
As a survivor of metastatic colorectal cancer diagnosed in 1995, Barry was obliged to seek health care outside of Canada to fight his disease. His judgement, obtained in the Superior Court of Quebec in 1999, serves as a leading precedent in Canada for the reimbursement of out of country health care.
Ontario's first Chief Scientist
Dr. Shoichet, PhD, O.C., O. Ont., NAE, is a world-leading expert in the study of polymers for drug delivery and in tissue regeneration, where she focuses on spinal cord injuries, strokes and blindness.
She has published more than 575 research papers, patents and abstracts, delivered more than 350 lectures worldwide, and trained close to 200 scientists in her lab. Dr. Shoichet has founded three spinoff companies based on her research. A passionate communicator, she launched a social media initiative, Research2Reality, to engage the public and promote the importance of research.
Dr. Shoichet has won 44 prestigious national and international awards, including the Killam Prize for Engineering and the L’Oreal-UNESCO For Women in Science Awards. She is the only person ever to be inducted into all three of Canada’s National Academies: the Canadian Academy of Sciences of the Royal Society of Canada, the Canadian Academy of Engineering, and the Canadian Academy of Health Sciences. She has been an appointed to the Order of Ontario and the Order of Canada, and is the recipient of the Queen Elizabeth II Diamond Jubilee Award.
Dr. Shoichet is a Tier 1 Canada Research Chair, and will continue in her work as a professor at the University of Toronto while serving as Ontario’s first Chief Scientist.
Photo credit: Brigitte Lacombe
Professor of Medicine and Medical Microbiology, University of Manitoba; and Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada
Dr. Frank Plummer is a Distinguished Professor at the University of Manitoba. In 1984 he moved to Kenya where he directed the University of Manitoba/Nairobi collaboration which was at the forefront of research on the HIV epidemic in Africa. From 2000 to 2014 he was Scientific Director of the National Microbiology Laboratory (Winnipeg) of the Public Health Agency of Canada. After that he was Senior Advisor to the President and Chief Public Health Officer of the Public Health Agency of Canada until 2017.
Dr. Plummer is recognized in Canada and abroad for his work in public health and science, having published more than 400 original articles in peer reviewed journals. He has received numerous honors, including his appointment as Officer of the Order of Canada, the Order of Manitoba, honorary degrees from McMaster University and the University of Calgary and receiving a grant from the Grand Challenges in Global Health initiatives of the Bill & Melinda Gates Foundation for his HIV research. Other awards include the Rh Institute Award; an Achievement Award from the American Venereal Disease Association; Fellowship, Scholarship, Scientist and Senior Scientist awards from the Medical Research Council of Canada; the I.S. Ravdin Award in the Basic Sciences from the American College of Surgeons; the St. Boniface Hospital Research Foundation International Award for work on HIV/AIDS in Africa, the Canadian Institutes of Health Research Researcher of the Year in 2007, the Scopus Award from the Hebrew University of Jerusalem, the Killam Prize for medical research, the Prix Galien and the Gairdner Foundation, Wightman Award. He also has received achievement awards from Nigerians in Diaspora and the Kenyan Association of Manitoba.
From 2001 to 2014 he was Canada Research Chair of the Canadian Institutes of Health Research. He has also been elected to the American Society of Clinical Investigation and the Association of American Physicians, has served as an advisor to the National Academy of Sciences in the US, and as a consultant to the World Bank, the World Health Organization, and the Governments of Kenya, India and Lesotho.
Dr. Plummer received his medical degree from the University of Manitoba in 1976 and trained in internal medicine and infectious diseases at the University of Southern California, the University of Manitoba, the University of Nairobi, and the Centers for Disease Control in Atlanta. He joined the University of Manitoba faculty in 1984 and is currently Distinguished Professor at the University of Manitoba in Medical Microbiology and Community Health Sciences. During his research career in Nairobi, Dr. Plummer published many articles on HIV/AIDS that have changed global public health policy. While he was Scientific Director of the National Microbiology Laboratory Dr. Plummer oversaw the development of VSV-Ebov (the vaccine that was successfully trialed in West Africa in 2015).
President, AstraZeneca Canada
Ed Dybka is the President of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies.
Mr. Dybka has more than 25 years of experience in the Canadian pharmaceutical industry. In 2012, he led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases and affiliated with Almirall S.A., with headquarters in Barcelona, Spain.
Prior to establishing Almirall in Canada, Mr. Dybka held a number of executive roles at GlaxoSmithKline Canada from 2004 to 2012, including Vice President of Marketing, Sales and Public Affairs & Reimbursement. During this time, he was accountable for the marketing and sales of all GSK pharmaceutical products, including specialty care, oncology and vaccines, achieving strong commercial performance and employee engagement. Earlier in his career, Mr. Dybka held progressively senior roles in product management and product development, as well as sales, at Glaxo Wellcome Canada Inc. and Zeneca Pharma Inc.
Mr. Dybka is currently a Director on the Board of Life Sciences Ontario, an organization that represents and promotes the province's vibrant and diverse life sciences sector. He has served on a number of other Boards, including the George Hull Centre for Children and Families, the Pharmaceutical Advertising and Advisory Board, the Canadian Pharmaceutical Distribution Network, and The Mississauga Board of Trade.
Mr. Dybka holds a Bachelor of Science degree in Toxicology from the University of Toronto. He lives in Toronto with his wife and two children.
Professor and Canada Research Chair in Bioethics at the Rotman Institute of Philosophy at Western University
Charles Weijer is Professor and Canada Research Chair in Bioethics at the Rotman Institute of Philosophy at Western University in London, Canada. He is the leading expert on the ethics of randomized controlled trials. Publications on the duty of care in clinical research, the ethical analysis of study benefits and harms, and empowering communities in research have been broadly influential.
From 2008–2013 Charles co-led a collaboration that produced the first international ethics guidelines for cluster randomized trials. From 2014–2018 he collaborated with Dr. Adrian M. Owen on a project exploring the ethics of functional neuroimaging after severe brain injury. Charles’ current work explores ethical issues in pragmatic randomized controlled trials that evaluate health interventions in real-world conditions to better inform patients, health providers and health systems managers. This project, funded by the Canadian Institutes of Health Research (2017–2021), brings together a research team comprising philosophers, biostatisticians and trialists from five countries. In 2008, Charles co-founded the Rotman Institute of Philosophy, which is dedicated to fostering collaboration between the humanities and the sciences, and served as the Institute’s first director. In 2014, he received Western’s Hellmuth Prize for Achievement in Research, and, in 2016, he was elected to the Royal Society of Canada.
Director Evidence Generation, Medical Affairs, Hoffmann-La Roche
Michael Duong is the Director for Evidence Generation in Medical Affairs for Hoffmann-La Roche Limited. In this role, Michael manages a team responsible for medical research in Canada, including clinical trials, real world data sciences, health outcomes research, and biostatistics. Prior to that, Michael led Health Economics at Roche in the Reimbursement and Health Economics Department. In that role, Michael provided expertise and guidance over the health economic and outcomes research activities conducted at Roche Canada.
Prior to that Michael spent three years in health care consulting, specializing in health economics and outcomes research, and medical communications. Michael received his undergraduate degree in Biology and Pharmacology and a Ph.D. in Medical Sciences with a specialization in Neuroscience, both from McMaster University.
Acting Director | University of Toronto Practice-Based Research Network (UTOPIAN) Associate Professor, DFCM, University of Toronto Scientist, North York General Hospital, Co-investigator, Diabetes Action Canada (DAC)
Dr Greiver’s work centers on using Canada’s increasingly large amounts of electronic health data to improve the health and lives of Canadians; diabetes is now a critical health issue for more Canadians than ever.
She oversees the Electronic Medical Record data system as well as clinical research activities for UTOPIAN, the University of Toronto Practice Based Research Network (PBRN), which includes over 1,400 family physicians and is the largest PBRN in Canada. UTOPIAN partners front line providers and academic researchers, providing insights into what is working and what could work better in primary care.
She is working with the Leadership of Diabetes Action Canada on the launch of a National Diabetes Repository; the Repository will combine multiple sources of data, including information added by patients living with diabetes on their health and well being. It is intended to offer patients new ways to access and use their data and enhanced options to engage and participate in care and research positioned to be meaningful and relevant to them.
President & CEO, LSO
Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO), the industry voice for the life sciences sector in Ontario. LSO is a member-driven organization that represents and promotes the province’s vibrant and diverse life sciences sector. LSO collaborates with governments, academia, industry and other life science organizations in Ontario and across Canada to promote and encourage commercial success throughout this diverse sector.
Jason obtained his PhD in Chemistry from the University of Massachusetts and his undergraduate degree from the University of Waterloo. Following graduate school, Jason returned to Ontario and worked in the pharmaceutical industry as a research scientist developing scalable manufacturing processes of active pharmaceutical ingredients. In 2007, he joined the Ministry of Economic Development and Trade (MEDT) where he led a team of senior advisors dedicated to growing Ontario's life sciences and information and communication technologies (ICT) sectors. During his time at MEDT, Jason was integral to the development of a number of strategic policy initiatives and spearheaded negotiations with several major ICT and life sciences companies that resulted in significant new investments in the province.
Jason joined LSO as Executive Director in October, 2011 and was appointed as President and CEO in April, 2014.
Futures Strategist, Saint Elizabeth
Zayna is a Futures Strategist with Saint Elizabeth a health company with a major focus on home care. In 2017 she spent the year on secondment to the REshape Health Innovation Centre at Radboud university medical centre in Nijmegan, Netherlands where she led several initiatives to advance health innovation in the country. From 2014 to 2017 Dr. Khayat lead health system innovation with MaRS Discovery District, a major innovation hub based in Toronto. At MaRS, Zayna and her team helped smooth the path to adoption of innovation by healthcare systems in Ontario and around the world.
Zayna is adjunct faculty with the Rotman School of Management in the Health Sector Strategy stream where she teaches a health MBA course on Healthcare Innovation. Dr. Khayat was previously a senior leader and adjunct faculty member with the International Centre for Health Innovation at the Ivey School of Business at Western University.
From 2010-2012, Zayna was an associate partner with SECOR Consulting/KPMG Canada. There, Zayna worked with medium and large sized public and private health and life sciences organizations in Ontario and nationally on issues of strategy and management. Prior to joining SECOR-KPMG, Zayna was a Principal with the Toronto office of The Boston Consulting Group (BCG), a global management consulting firm, from 2001 to 2010.
Zayna earned her Ph.D. in biochemistry from the University of Toronto / Hospital for Sick Children where she was a scholar of the Canadian Institutes of Health Research, studying how insulin and exercise regulate blood glucose in the muscle, and why/where this process breaks down during disease states such as diabetes. She has more than 10 publications and chapters in international journals and textbooks.
Zayna completed undergraduate studies in biochemistry at the University of Windsor, where she earned the President's Medal for top all around graduate of the University (1996) and the Board of Governor's Medal for top graduate of the biochemistry department.
Zayna speaks proficiently in French and Arabic, and is based out of Toronto where she lives with her husband and 3 children.
Senior Clinical Operations Manager, Clinical Research, AbbVie
Chantal Lacasse has over 20 years of experience in the pharmaceutical industry. She began her career doing basic research at the CHUS working on platelet activating factor on epithelial cells which was her PhD thesis. She then moved to Montreal to perform her post doctorate in hematopoiesis at the Clinical Research Institute of Montreal. Chantal then joined Phoenix International as an Associate Director for Clinical Projects.
In 1998 she moved to Abbott Laboratories/Abbvie Corporation in Clinical Research where she quickly rose through the ranks to the position of Senior Clinical Operations Manager, Global Medical Affairs. She now oversees all operational aspects of the Clinical Research Department in the conduct of observational studies across a diverse range of therapeutic areas. In this role Chantal supports her team in the development of innovative and strategic recruitment, engagement and retention initiatives.
In her free time, Chantal enjoys cycling while enjoying the scenery.
Professor, Health Research Methods, Evidence, and Impact, McMaster University
Julia Abelson is a professor of health policy in the Department of Health Research Methods, Evidence & Impact at McMaster University and a member of the Centre for Health Economics and Policy Analysis, where she was director from 2006-2011.
Since her appointment to McMaster in 1998, she has held numerous research grants and awards from provincial and national funding agencies. She is a past recipient of a Canadian Institutes of Health Research New Investigator award, an Ontario Ministry of Health and Long-Term Care Career Scientist award and held a Harkness Fellowship in Healthcare Policy from the U.S. based Commonwealth Fund. She obtained her M.Sc. in Health Policy and Management from the Harvard School of Public Health and her doctorate in social and policy sciences at the University of Bath, U.K.
Dr. Abelson’s research program is guided by a long-standing interest in how the public interacts with health systems as patients, community members, voters and taxpayers. These interests have provided the foundation for numerous research studies focused on the design and evaluation of processes for engaging the public and patients in health system decision-making
Through her research, she has developed productive and long-standing partnerships with a wide range of policy makers and health system managers at the provincial and regional governance levels across the country and is regularly invited to advise policy decision makers and health system managers on the design, implementation and evaluation of public engagement processes.
Director, Patient Engagement, Ethics and International Affairs, CADTH
Ken Bond is responsible for the strategic and operational direction of patient engagement activities for CADTH’s pharmaceutical review, health technology management, and scientific advice programs. He also oversees the development of methods to address ethical issues in HTA (health technology assessment) and CADTH’s international partnerships.
Ken has held research positions at the Institute of Health Economics and the Alberta Research Centre for Health Evidence (both in Edmonton) and has over a decade of experience coordinating and producing health technology assessments and methods guidance for CADTH, Alberta Health, and the United States’ Agency for Health Care Research and Quality (AHRQ).
Ken is an associate editor for the International Journal for Technology Assessment in Health Care, the co-chair of the HTAi Ethics Interest Group, and a Steering Committee member of the HTAi Patient and Citizen Involvement Interest Group.
CEO, Life Saving Therapies
As a cancer survivor and former caregiver, John-Peter is passionate about the work of the Life-Saving Therapies Network (LSTN), www.lifesavingtherapies.com. LSTN produces and advocates for actionable recommendations that will get precision treatments of lethal diseases to patients faster and cheaper. The specific focus is on regulatory and clinical research reform, as well as timely and thorough reimbursement for treatments and companion diagnostics.
John-Peter is CEO of LSTN, has served as co-Chair of the Advocacy Committee of Lung Cancer Canada, a member of the Research Advisory Group of the Canadian Partnership Against Cancer and an advisor to the Ottawa Regional Cancer Foundation.
His book with Lisa Newman, Journeys in Cancerland, is based on his experiences and observations of the healthcare system as a cancer patient. He has published in peer reviewed journals, newspapers and other formats on regulatory and healthcare reform.
John-Peter is a Fellow of the Institute of Certified Management Consultants of Ontario. He holds a B.A. in Psychology, an M.A. in Experimental Psychology, and a Ph.D. in Psychology and Community Services. In the public sector, he has been principal consultant in restructuring the management of the House of Commons, Supreme Court of Canada, Medical Research Council of Canada, Immigration and Refugee Review Board of Canada, HRDC, Canadian Commercial Corporation, to name a few. He coordinated the Inuit land claim that led to the formation of Nunavut.
In the private sector, he has served as CEO, board member and strategic advisor for publicly listed and private companies. He has also helped to raise hundreds of millions of dollars for nonprofit organizations and private sector companies.
President and CEO, Institute for Clinical Evaluative Sciences
Michael Schull is President, CEO and Senior Scientist at the Institute for Clinical Evaluative Sciences, and Professor in the Department of Medicine at the University of Toronto. His research focuses on health service utilization, quality of care, health system integration and patient outcomes, and the evaluation of health policy. His studies use administrative health datasets and linkages with clinical data, and he works closely with health system decision and policy makers.
Dr. Schull practices as an Emergency Medicine specialist at Sunnybrook Health Sciences Centre in Toronto.
Senior Scientist and Director, Clinical Epidemiology Program, Ottawa Hospital Research Institute and Professor, Department of Medicine, University of Ottawa
Dr. Fergusson is a Senior Scientist & Director, Clinical Epidemiology Program, at the Ottawa Hospital Research Institute. He is also a Full Professor, Departments of Medicine, Surgery, & of the School of Epidemiology and Public Health, University of Ottawa. Dr. Fergusson holds the position of Endowed Chair, OHRI/uOttawa, Clinical Epidemiology Program.
He holds a PhD (Honours) in Epidemiology and Biostatistics from McGill University and a Masters of Health Administration from the University of Ottawa. Dr. Fergusson’s clinical research interests are mainly in the field of transfusion medicine with a focus on transfusion alternatives and the effectiveness of blood products. His research interests also extend to the methodology and ethics of clinical trials and systematic reviews. Dr. Fergusson is also the co-lead of the Rethinking Clinical Trials (REaCT) Program which performs practical patient-focused research that ensures that patients receive optimal, safe, cost effective treatment. It includes the pragmatic evaluation of standard, usual care interventions using efficient informed consent, efficient routinely collected electronic administrative and clinical data, and immediate implementation of findings into routine TOH practice. Dr. Fergusson is a principal investigator on a number of large, peer-reviewed clinical trials in transfusion medicine including “Blood Conservation Using Antifibrinolytics: Randomized Trial in High-Risk Cardiac Surgery (BART)”, Age of Red Blood Cells in Premature Infants (ARIPI), “Age of Blood Evaluation (ABLE)”. Dr. Fergusson has contributed over 420 articles, abstracts, and book chapters to the medical literature.
Project Manager, MaRS EXCITE
Bio Coming Soon...
Surgical Oncologist and Scientist, Odette Cancer Centre / Sunnybrook Health Sciences Centre
Dr. Paul Karanicolas is a surgical oncologist in the Odette Cancer Centre and a scientist at the Sunnybrook Research Institute. His clinical practice is dedicated to patients with hepatobiliary, pancreatic, and gastrointestinal malignancies. Dr. Karanicolas received his medical degree at the University of Western Ontario where he also completed his general surgery residency training. He then completed a PhD in Health Research Methodology at McMaster University and a clinical fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center in New York.
The main focus of his research is designing and leading randomized controlled trials in surgical oncology. Dr. Karanicolas has spearheaded the establishment of the “HepatoPancreaticoBiliary Community of Surgical ONcologists: Clinical, Evaluative, and Prospective Trials Team (HPB CONCEPT Team)”, a Canada-wide consensus-based framework for liver and pancreas cancer research. He is the principal investigator on a CIHR-funded grant to develop high-impact clinical trials on behalf of this group and currently leads a national randomized controlled trial examining the impact of tranexamic acid on bleeding during liver resection. Dr. Karanicolas is the Odette Cancer Centre site representative to the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and is involved in several active trials.
Dr. Karanicolas also conducts research examining quality of life in patients undergoing surgery for cancer. Dr. Karanicolas’ team is implementing an electronic framework to integrate patient education and assessment of quality of life into routine care. He is also examining the impact of surveillance following cancer resection on patient satisfaction and quality-of-life.
Dr. Karanicolas is the surgical lead for the hepatic arterial infusion pump chemotherapy program at the Odette Cancer Centre. This is the first program of its kind in Canada and offers an additional therapeutic option for patients with colorectal liver metastases.
CTO Board Member and Patient & Public Advisory Group Member
Tina Ceroni has first-hand experience, both as a patient and clinical trial participant. In 2011 she became the recipient of a stem cell transplant for a rare neuromuscular disease called Stiff Person Syndrome in a clinical trial at the Ottawa Hospital. Today she is in long lasting remission.
Tina is currently a member of the Board of Directors for Clinical Trials Ontario and is a strong patient advocate for stem cell research, rare diseases and patient engagement. She is also the chair of the patient advisory committee for the Ontario Institute of Regenerative Medicine and is a member of the Stem Cell Oversight Committee for CIHR.
Tina is also actively involved with a number of other health organizations as a public speaker and patient representative and founded Share a Cell, an organization that aims to raise awareness and funds for stem cell research and rare diseases. Going through her personal health experience has affirmed a passion in her to give back and be a support to others.
Research Privacy Advisor, Provincial Health Services Authority, Ethicist, BC Cancer Research Ethics Board
Holly Longstaff is a PhD-prepared ethicist with a broad background in privacy and the ethics of health research. Holly is the ethicist for the BC Cancer Agency Research Ethics Board (REB) and is a member of Schulman Institutional Review Board’s Canadian panel. She is also the Research Privacy Advisor for the Provincial Health Services Authority (PHSA). Through her role as an ethicist and privacy advisor, Holly has extensive experience in reviewing proposed research studies for privacy and confidentiality requirements, and in helping researchers navigate the ethics and privacy requirements of their work.
Holly has also developed policy and related guidance documents for Health Canada and the Public Health Agency of Canada, created ethics, privacy and confidentiality educational materials for the Canadian Institutes of Health Research (CIHR) Ethics Office, and provided consulting services for a variety of organizations including the Canadian Clinical Trials Coordinating Centre and the BC Ethics Harmonization Initiative (BCEHI). She is currently collaborating on a CIHR grant held by principal investigator Dr. McGrail at UBC which focuses on consulting with the public about good governance models for data sharing and access to research resources.
Holly is passionate about supporting the research community in advancing ethically and privacy sound research, and committed to recommending practical ways to reduce and manage privacy risks in research.
CEO, Huntington Society of Canada
Bev Heim-Myers joined the Huntington Society of Canada in 2010 as Chief Executive Officer. Currently Bev is the Chair of the Canadian Coalition for Genetic Fairness. Bev is the past Treasurer of the Governing Council of the Health Charities Coalition Canada (HCCC) and is an active member of HCCC, a member of the Governing Council of the Neurological Health Charities of Canada (NHCC) and the previous National Population Health Study of Neurological Conditions (NPHSNC). Bev is also an Executive member of the Board of the International Huntington Association (IHA) acting as Vice President and a founding member of HD-COPE – a globally coordinated knowledge sharing mechanism to ensure the HD Community voice is shared, in a timely manner, with regulators, industry and researchers.
In 2015 Bev received the Health Charities Coalition of Canada Award of Distinction in recognition of leadership and outstanding support to the charitable health sector.
In 2016 Bev received the American Society of Human Genetics, Advocacy Award, together with Senator James Cowan. This award is in recognition of facilitating public awareness of genetics issues and for work done to move the protection of genetic test information forward in Canada.
Clinical Trialist, George & Fay Yee Centre for Healthcare Innovation
Dr. Lauren Kelly completed her Bachelors of Medical Sciences and Doctorate of Philosophy in Pharmacology at the University of Western Ontario. She also has a Masers of Science degree in Toxicology from the University of Birmingham in the U.K. Following her graduate studies, Lauren returned to her home town of Toronto, Ontario where she completed two post-doctoral fellowships in Clinical Epidemiology at the Hospital for Sick Children and at Mount Sinai Hospital. Dr. Kelly is a Certified Clinical Research Professional.
Her research focuses on neonatal and pediatric drug development and clinical trial methodology. She has been working in pediatric clinical research for the past decade with a focus on opioid exposure in pregnancy/early childhood and the development of research tools to design clinical trials that can inform evidence-based clinical care. Previously, she was a guest expert at the European Medicines Agency where they co-developed a tool for the justification of comparator (control arm) selection in pediatric clinical trials. Her current projects include leading an international consortium to develop a core outcome set for neonatal abstinences syndrome, establishing references ranges for very and extremely preterm infants, innovation in pediatric clinical trials (a SPOR funded, multi-centre trials initiative) and a collaboration with Clinical Trials Ontario & KidsCAN Trials to develop and disseminate training on innovative clinical trial design.
Caregiver Representative and Contributing Member, Neuroblastoma Canada
Kirby is a parent to two children - a boy and a girl. His daughter, Maya Kim, was diagnosed with neuroblastoma, on March 26th, 2010 as well as therapy induced myelodisplatic syndrome. Like most parents, Kirby wants to be involved as much as he can in Maya's treatment as well as contribute to the greater whole in the neuroblastoma community. By engaging in neuroblastoma.ca, he is hoping to unite and help the families in their journey through conquering this horrible disease.
Kirby is also a software research architect for a financial software company in Toronto. He is interested in big data solution in medicine with patient centric data aggregation and presentation . He is an avid motorcyclist who enjoys long distance rides across Canada and United States.
Health Policy Analyst, Information and Privacy Commissioner of Ontario
Joshua Shaw (LL.M., J.D., B.Sc. Hons.) provides policy analysis and advice on matters of health privacy to the Information and Privacy Commissioner of Ontario (IPC). Joshua was called to the bar of Ontario as a lawyer in 2017 after articling with the IPC, and obtained a Master of Laws from Dalhousie University, and Juris Doctor and Bachelor of Science from University of Manitoba.
Director, Clinical Health Services and Population Health Research, University of Calgary
Sabine Moritz, Dipl. Biol., M.Sc. CCRP, Director, Clinical, Health Services and Population Health Research at the University of Calgary - Sabine has 25 years of experience in developing and leading clinical trial programs both in Canada and in the UK. Before joining the University of Calgary, she led the Cancer Clinical Trials Program for Southern Alberta. Under her leadership a trial business unit and a trial launch/industry engagement office was created, leading to faster activation times, increased industry partner satisfaction and significant growth in clinical trial activities.
Global Patient Affairs Lead, Pfizer
Roslyn F. Schneider, MD, MSc, FACP, FCCP Dr. Schneider is the Global Patient Affairs (GPA) Lead within Pfizer's Chief Medical Office following roles in Medical Affairs, Medicine Development and Medical Strategy at Pfizer since 2006. Her team drives more systematic, end to end patient centricity at Pfizer. She received her BS from the Sophie Davis School of Biomedical Education of the City College of New York, her MD from Mount Sinai School of Medicine, and MSc in Pharmaceutical Medicine from Hibernia College.
Dr. Schneider is a retired Clinical Professor of Medicine of Albert Einstein College of Medicine, Internist, Pulmonologist, Intensivist and was in clinical practice and academia for twenty years. She published in areas of patient centricity, pulmonary complications of HIV infection, venous thromboembolic disease, medical ethics and medical education. She is a fellow of both the American College of Physicians and the American College of Chest Physicians.
Assistant Professor, eHealth Graduate Program Coordinator, Department of Computing and Software, McMaster University
Reza Samavi is currently an assistant professor at the Department of Computing and Software at McMaster University where he holds the position of the department lead for the eHealth graduate program. Reza received his PhD and Masters from the University of Toronto and his main research interests are in the fields of data security and privacy, semantic web, ontology engineering, health data analytics and collaborative research architecture. Reza is a collaborating researcher with the SOSCIP Consortium, IBM, Autodesk and Hamilton Health Sciences.
For his research on information privacy Reza has received the Privacy Technologies Research Award from the IBM Center for Advanced Studies and the Privacy By Design Research Award from the Information and Privacy Commissioner of Ontario.
Patient Education Support Manager, Ontario, Leukemia & Lymphoma Society
Sarah is the Patient Education Support Manager for Ontario, with the Leukemia & Lymphoma Society of Canada. She leads healthcare professional and patient education events, works closely with cancer centers for awareness and community outreach, providing personalized support to blood cancer patients.
With over ten years of experience in the health charity sector, she’s worked with various chronic diseases and health promotion at Diabetes Canada, Osteoporosis Canada and CAMH. Her focus included program development, research knowledge translation and designing health tools for patients.
Sarah holds a Bachelors of Health Sciences from Western University and a Masters of Science in Public Health from Queen Mary, University of London.